Printify
Women's V-Neck Tee (Supporter Jersey)
Women's V-Neck Tee (Supporter Jersey)
Couldn't load pickup availability
Show your support with style and purpose in the Strength in Support V-Neck Tee, designed for those who stand by pancreatic cancer fighters and survivors. This Bella+Canvas v-neck shirt proudly displays the word “Supporter” on the back like a sports jersey—a powerful statement of solidarity and encouragement.
Crafted from lightweight, breathable 100% cotton (with heathered colors in a soft cotton-poly blend), this tee is perfect for any casual or semi-formal setting. Its stylish retail fit and V-neckline ensure a flattering silhouette, making it a versatile addition to your wardrobe. Each shirt is manufactured under Fair Labor Association guidelines, meaning you can feel good about its ethical and sustainable production.
With 40% of all revenue from this tee going directly to pancreatic cancer research, every purchase supports the fight against this disease, bringing us closer to a cure. Wear your support with pride and purpose.
- Lightweight, breathable fabric (4.2 oz/yd² or 142 g/m²) for comfortable, year-round wear
- Stylish V-neckline with a tailored retail fit
- Tear-away label for added comfort
- 100% cotton (heather colors: 52% cotton, 48% polyester; Athletic Heather: 90% cotton, 10% polyester)
- Ethically produced under Bella+Canvas’s Platinum WRAP and Fair Labor Association certifications
Share


Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...